North America Blood Glucose Monitoring Market Size

Statistics for the 2023 & 2024 North America Blood Glucose Monitoring market size, created by Mordor Intelligence™ Industry Reports. North America Blood Glucose Monitoring size report includes a market forecast to 2028 and historical overview. Get a sample of this industry size analysis as a free report PDF download.

INSTANT ACCESS

Market Size of North America Blood Glucose Monitoring Industry

North America Blood Glucose Monitoring Market Size
Study Period 2018 - 2028
Base Year For Estimation 2021
Forecast Data Period 2023 - 2028
Market Size (2023) USD 13.71 Billion
Market Size (2028) USD 25.40 Billion
CAGR (2023 - 2028) 13.13 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

North America Blood Glucose Monitoring Market Analysis

The North America Blood Glucose Monitoring Market size is estimated at USD 13.71 billion in 2023, and is expected to reach USD 25.40 billion by 2028, growing at a CAGR of 13.13% during the forecast period (2023-2028).

In North America, diabetes incidence for Type-2 diabetes and other diabetes forms was numerically higher in individuals with COVID-19. Insulin resistance and impaired insulin secretion have been described in individuals without diabetes history who recovered from SARS-CoV-2 infections. It has been suggested that diagnosis and treatment of post-COVID-19 syndrome require integrated rather than disease-specific approaches.

Over the past decade, there has been a tremendous increase in the diabetic population globally. Several reports and surveys documented a drastic increase in the diabetic population based on the changes in lifestyles and habits. The growing diabetic population drives blood monitoring devices, such as CGM. Nearly 90% of Type-1 diabetic patients in developed countries use a glucometer. Nearly 50% of Type-2 patients are expected to use a glucometer during the forecast period.

North America dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and the launch of new drugs. The United States is expected to grow tremendously during the forecast period, owing to factors such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region.

Therefore, owing to the factors mentioned above, the studied market is anticipated to witness growth over the analysis period.